ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934

Also written as “TQB2934 injection” and “TQB2934 injection (subcutaneous injection)”.

In Sino Biopharmaceutical’s pipeline, BCMA/CD3双抗. Its studies are mostly in Multiple Myeloma · Amyloidosis, led by Sino Biopharmaceutical.

Drug pageAnti-CD3/Anti-BCMA Bispecific Antibody TQB2934: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 29, 20264 company-led studies, 4 open or runningNext primary completion: Oct 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical44 open or runningphase 3since Apr 29, 2026Dec 1, 2022Oct 2027phase 1 · NCT07179679

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 1, 2022First study: phase 1 study in Multiple MyelomaFirst studyNCT05646758 · 140 planned · China
  2. Sep 9, 2025Phase 1 study in Multiple MyelomaNCT07179679 · 42 planned · China
  3. Nov 25, 2025Phase 2 study in Systemic Light Chain AmyloidosisNCT07266116 · 70 planned · China
  4. Apr 29, 2026Phase 3 study in Multiple MyelomaPhase 3 reachedNCT07569757 · 260 planned · China

Ahead

  1. Oct 2027Primary completion: phase 1 study in Multiple MyelomaNCT07179679
  2. Dec 2028Primary completion: phase 3 study in Multiple MyelomaNCT07569757
  3. Feb 2029Primary completion: phase 2 study in Systemic Light Chain AmyloidosisNCT07266116

TargetBeta

“BCMA/CD3双抗”the company's pipeline, read by Claude · source
“A T-cell engaging, human, bispecific, immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and CD3 antigen found on T-lymphocytes, ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
elranatamabrulePfizerphase 415
linvoseltamabruleRegeneron Pharmaceuticalsphase 413
teclistamabruleJohnson & Johnsonphase 411
etentamigAbbViephase 311
ramantamigJohnson & Johnsonphase 38
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
cizutamigruleUCBphase 25
vonsetamigruleRegeneron Pharmaceuticalsphase 23
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
LVV Expressing VSV Glycoprotein/Anti-CD3 scFv Containing Transgene Encoding for Anti-BCMA CAR KLN-1010rulekelonia-therapeutics-incphase 11

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07569757Multiple Myeloma · China3Not yet recruitingDec 2028260
NCT07266116Systemic Light Chain Amyloidosis · China2RecruitingFeb 202970
NCT07179679Multiple Myeloma · China1RecruitingOct 202742
NCT05646758Multiple Myeloma · China1RecruitingOct 2024140

How it is read

Names in the registry

  • “TQB2934 injection”, 3 entries
  • “TQB2934 injection (subcutaneous injection)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.